Hanna Y Irie, MD, PhD
- ASSISTANT PROFESSOR | Medicine, Hematology and Medical Oncology
- ASSISTANT PROFESSOR | Oncological Sciences
Specialties:Hematology-Oncology, Cancer (Oncology)
Research Topics:Anti-Tumor Therapy, Cancer, Cell Biology, Cell Transformation, Growth Factors and Receptors, Protein Kinases
I am a medical oncologist specializing in the care of patients with breast cancer. As a physician-scientist, I also lead a research laboratory that is focused on developing targeted therapies tailored for specific breast cancer subtypes and for individual patients. I have a particular interest in better understanding triple negative breast cancers, with the goal of integrating genetic analysis to the development of improved treatments for our patients.
I am co-PI of the Breast Tumor Biospecimen Repository, which is a bank of patient breast tumors; analysis of these tumors will provide insights into the genetic changes that determine sensitivity to specific targeted therapies for breast cancer. I am also co-PI of a study investigating the use of patient-derived xenograft models as a model for chemotherapy treatment sensitivity for patients with triple negative breast cancers; if successful, these models may be used in the future to help us better tailor treatments for individual patients. My research laboratory has identified several new candidate therapeutic targets for Her2+ and triple negative breast cancers resistant to current treatments, and we are working to translate our findings to clinical studies and trials.
I am a member of the American Society of Clinical Oncology and the American Association for Cancer Research.
MD/PHD, Harvard Medical School
BA, Harvard University
Clinical Fellow, Dana-Farber Cancer Institute
Instructor, Dana-Farber Cancer Institute/Harvard Medical School
Intern/Resident, Massachusetts General Hospital
MD, Harvard Medical School
PhD, Harvard Medical School
Research Fellow, Harvard Medical School
Residency, Internal Medicine, Massachusetts General Hospital
Fellowship, Hematology/Oncology, Dana Farber Cancer Institute
Breast Cancer Alliance Exceptional Project Grant
Breast Cancer Research Foundation Grant
AACR-Genentech BioOncology Career Development Award for Research on the Her Family in Cancer
Susan G Komen Career Catalyst Award
Dana Farber Cancer Institute SPORE in Breast Cancer Career Development Award
Terri Brodeur Breast Cancer Research Foundation Grant
K08 Mentored Clinical Scientist Award
AACR Scholar-in-Training Award
ASCO Young Investigator Award
Ravichandran KS, Pratt JC, Sawasdikosol S, Irie HY, Burakoff SJ. Coreceptors and adapter proteins in T-cell signaling [review]. Annals of the New York Academy of Sciences 1995 Sep; 766.
Irie HY, Pearline RV, Grueneberg D, Hsia M, Ravichandran P, Kothari N, Natesan S, Brugge JS. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. The Journal of cell biology 2005 Dec; 171(6).
McKay DB, Irie HY, Hollander G, Ferrara JL, Strom TB, Li Y, Burakoff SJ. Antigen-induced unresponsiveness results in altered T cell signaling. Journal of immunology (Baltimore, Md. : 1950) 1999 Dec; 163(12).
Irie HY, Jaklitsch MT, Shaffer K, Weinstein M, Salgia R. Unusual problems in breast cancer and a rare lung cancer case. Case 4. Primary lymphoepithelioma-like carcinoma of the lung. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003 Jun; 21(11).
Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV, Cantley LC, Brugge JS. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer research 2005 Dec; 65(23).
Irie HY, Mong MS, Itano A, Crooks ME, Littman DR, Burakoff SJ, Robey E. The cytoplasmic domain of CD8 beta regulates Lck kinase activation and CD8 T cell development. Journal of immunology (Baltimore, Md. : 1950) 1998 Jul; 161(1).
Fragoso RC, Pyarajan S, Irie HY, Burakoff SJ. A CD8/Lck transgene is able to drive thymocyte differentiation. Journal of immunology (Baltimore, Md. : 1950) 2006 Nov; 177(9).
Schafer ZT, Grassian AR, Song L, Jiang Z, Gerhart-Hines Z, Irie HY, Gao S, Puigserver P, Brugge JS. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 2009 Sep; 461(7260).
Irie HY, Shrestha Y, Selfors LM, Frye F, Iida N, Wang Z, Zou L, Yao J, Lu Y, Epstein CB, Natesan S, Richardson AL, Polyak K, Mills GB, Hahn WC, Brugge JS. PTK6 regulates IGF-1-induced anchorage-independent survival. PloS one 2010; 5(7).
Tamimi RM, Colditz GA, Wang Y, Collins LC, Hu R, Rosner B, Irie HY, Connolly JL, Schnitt SJ. Expression of IGF1R in normal breast tissue and subsequent risk of breast cancer. Breast cancer research and treatment 2011 Jul; 128(1).
Irie HY, Ravichandran KS, Burakoff SJ. CD8 beta chain influences CD8 alpha chain-associated Lck kinase activity. The Journal of experimental medicine 1995 Apr; 181(4).